0.67
+0.0622(+10.22%)
Currency In USD
| Previous Close | 0.61 |
| Open | 0.61 |
| Day High | 0.67 |
| Day Low | 0.6 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.32 |
| Volume | 600,384 |
| Average Volume | 2.63M |
| Market Cap | 48.28M |
| PE | -0.5 |
| EPS | -1.34 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 1.2 |
| Change | 0.06 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $42.88 as of January 05, 2026 at a share price of $0.671. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $259.11 as of January 05, 2026 at a share price of $0.671.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
GlobeNewswire Inc.
Dec 15, 2025 9:05 PM GMT
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the poten
IO Biotech Announces Participation in Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 26, 2025 3:46 PM GMT
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation in the 8th
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myel